Who makes Chemopreventive Agent - SPAQ?

Chemopreventive Agent - SPAQ is developed by Malaria Consortium.

What development phase is Chemopreventive Agent - SPAQ in?

Chemopreventive Agent - SPAQ is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Chemopreventive Agent - SPAQ

Malaria Consortium · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Chemopreventive Agent - SPAQ
Also known as	sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ)
Sponsor	Malaria Consortium
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness of Seasonal Malaria Chemoprevention in Nampula Province, Mozambique: Type Two Hybrid Implementation Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chemopreventive Agent - SPAQ CI brief — competitive landscape report
Chemopreventive Agent - SPAQ updates RSS · CI watch RSS
Malaria Consortium portfolio CI